International consensus group on depression prevention in bipolar disorder

Journal of Clinical Psychiatry

Volumn 72, Issue 10, 2011, Pages 1295-1310

  Frye, Mark A ^a   Ha, Kyooseob ^b,c   Kanba, Shigenobu ^d   Kato, Tadafumi ^e   McElroy, Susan L ^f   Özerdem, Ayşegül ^g   Vázquez, Gustavo ^h   Vieta, Eduard ⁱ  

^a MAYO CLINIC   (United States)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University   (South Korea)

^d KYUSHU UNIVERSITY   (Japan)

^e RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^f UNIVERSITY OF CINCINNATI   (United States)

^g DOKUZ EYLUL UNIVERSITY   (Turkey)

^h UNIVERSITY OF PALERMO   (Argentina)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADJUVANT THERAPY; ARGENTINA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; COMORBIDITY; CONSENSUS; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; JAPAN; KOREA; LONG TERM CARE; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); METABOLIC DISORDER; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; STUDY DESIGN; TURKEY (REPUBLIC); WEIGHT GAIN;

EID: 80054896090     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10123co1c     Document Type: Note

References (93)

1. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241-251. doi:10.101/archgenpsychiatry.201.12 PubMed
2. Judd LL, Schettler PJ, Akiskal HS, et al. Long-term symptomatic status of bipolar I vs bipolar II disorders. Int J Neuropsychopharmacol. 2003;6(2):127-137. doi:10.1017/S1461457030341 PubMed (Pubitemid 36850965)
3. Gitlin MJ, Abulseoud O, Frye MA. Improving the design of maintenance studies for bipolar disorder. Curr Med Res Opin. 2010;26(8):1835-1842. doi:10.185/030795.2010.489830 PubMed
4. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65(3):432-441. doi:10.408/JCP. v65n0321 PubMed
5. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163(2):247-256. doi:10.176/api.ajp.163.2.247 PubMed (Pubitemid 44480844)
6. Keck PE Jr, Calabrese JR, McQuade RD, et al., for the Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67(4):626-637. doi:10.408/JCP.v67n0414 PubMed (Pubitemid 43764240)
7. Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008;109(3):251-263. doi:10.1016/j.jad.208.06.01 PubMed
8. Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebocontrolled, double-blind trial. J Clin Psychiatry. 2010;71(2):130-137. doi:10.408/JCP. 09m05482yel PubMed
9. Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010;68(2):156-162. doi:10.1016/j.biopsych.2010.01.015 PubMed
10. Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009;11(8):827-839. doi:10.1/j.139-5618.209.0761.x PubMed
11. BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomized open-label trial. Lancet. 2010;375(9712):385-395. doi:10.1016/S0140-6736(09)61828-6 PubMed
12. van der Loos ML, Mulder P, Hartong EG, et al., for the LamLit Study Group. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord. 2011;13(1):111-117. doi:10.1/j.139-5618.201.087.x PubMed
13. van der Loos ML, Mulder PG, Hartong EG, et al., for the LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223-231. doi:10.408/JCP.08m04152 PubMed
14. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry. 2007;64(4):419-426. doi:10.101/archpsyc.64.4.419 PubMed
15. Altshuler LL, Post RM, Black DO, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67(10):1551-1560. doi:10.408/JCP.v67n109 PubMed (Pubitemid 44787437)
16. Frye MA, Yatham LN, Calabrese JR, et al. Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J Clin Psychiatry. 2006;67(11):1721-1728. doi:10.408/JCP.v67n108 PubMed (Pubitemid 44955152)
17. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850. doi:10.101/archpsyc.58.9.84 PubMed (Pubitemid 32979302)
18. Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med. 2006;68(5):684-691. doi:10.1097/01.psy.0237316.09601.8 PubMed (Pubitemid 44454636)
19. Perron BE, Howard MO, Nienhuis JK, et al. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2009;70(10):1407-1415. doi:10.408/JCP.08m04586yel PubMed
20. Goldstein BI, Fagiolini A, Houck P, et al. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord. 2009;11(6):657-662. doi:10.1/j.139-5618.209.0735.x PubMed
21. Kemp DE, Gao K, Chan PK, et al. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord. 2010;12(4):404-413. doi:10.1/j.139-5618.2010.0823.x PubMed
22. Tsai SY, Lee CH, Kuo CJ, et al. A retrospective analysis of risk and protective factors for natural death in bipolar disorder. J Clin Psychiatry. 2005;66(12):1586-1591. doi:10.408/JCP.v6n1215 PubMed (Pubitemid 43068700)
23. Stafford L, Berk M. The use of statins after cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypothesis of depression? J Clin Psychiatry. 2011;72(9):1229-1235. doi:10.408/JCP.09m05825blu PubMed
24. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry. 2006;188(1):46-50. doi:10.192/bjp.18.1.46 PubMed (Pubitemid 43021926)
25. Maina G, Salvi V, Vitalucci A, et al. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord. 2008;110(1-2):149-155. doi:10.1016/j.jad.207.12.23 PubMed
26. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160(1):112-117. doi:10.176/api.ajp.160.1.12 PubMed (Pubitemid 36042434)
27. Newcomer JW, Meyer JM, Baker RA, et al. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr Res. 2008;106(2-3):300-307. doi:10.1016/j.schres.208.09.02 PubMed
28. Yood MU, DeLorenze G, Quesenberry CP Jr, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf. 2009;18(9):791-799. doi:10.102/pds.1781 PubMed
29. Torrent C, Amann B, Sánchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118(1):4-18. doi:10.1/j.160-047.208.01204.x PubMed (Pubitemid 351832022)
30. Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry. 2006;163(7):1199-1201. doi:10.176/api.ajp.163.7.19 PubMed (Pubitemid 44464447)
31. Milano W, Grillo F, Del Mastro A, et al. Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study. Adv Ther. 2007;24(1):123-134. doi:10.107/BF02850 PubMed (Pubitemid 46705389)
32. Ehret M, Goethe J, Lanosa M, et al. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry. 2010;71(10):1286-1292. doi:10.408/JCP.09m05274yel PubMed
33. Cole DP, Thase ME, Mallinger AG, et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry. 2002;159(1):116-121. doi:10.176/api.ajp.159.1.16 PubMed (Pubitemid 41070736)
34. Frye MA, Yatham L, Ketter TA, et al. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. Acta Psychiatr Scand. 2009;120(1):10-13. doi:10.1/j.160-047.208.01343.x PubMed
35. Baskin HJ, Cobin RH, Duick DS, et al., for the American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8(6):457-469. PubMed
36. Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58(1):85-91. doi:10.176/api.ps.58.1.85 PubMed
37. American Psychiatric Association. Guideline Watch: Practice Guideline for the Treatment of Patients With Bipolar Disorder, Second Edition. Washington, DC: American Psychiatric Association; 2005 http://www.psychiatryonline.com/ pracGuide/pracGuideTopic-8.aspx. Accessed July 28, 2011.
38. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebocontrolled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163-174. PubMed doi:10.408/JCP.08m04942gre
39. Pacchiarotti I, Valentí M, Colom F, et al. Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J Affect Disord. 2011;129(1-3):321-326. doi:10.1016/j.jad. 2010.07.036 PubMed
40. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-1722. doi:10.1056/NEJMoa064135 PubMed (Pubitemid 46658703)
41. Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry. 2002;63(6):508-512. doi:10.408/JCP.v63n0607 PubMed (Pubitemid 34680359)
42. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189(2):124-131. doi:10.192/bjp.bp.105.013045 PubMed (Pubitemid 44231270)
43. Wehr TA, Goodwin FK. Do antidepressants cause mania? Psychopharmacol Bull. 1987;23(1):61-65. PubMed (Pubitemid 17111664)
44. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression (published correction appears in Arch Gen Psychiatry. 2004;61(2):176). Arch Gen Psychiatry. 2003;60(11):1079-1088. doi:10.101/archpsyc.60.1.1079 PubMed (Pubitemid 37429647)
45. Pacchiarotti I, Valentí M, Bonnin CM, et al. Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol. 2011;21(5):362-369. doi:10.1016/j.euroneuro.2010.10.02 PubMed
46. Pacchiarotti I, Mazzarini L, Colom F, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand. 2009;120(6):429-440. doi:10.1/j.160-047.209.01471.x PubMed
47. van der Loos ML, Mulder P, Hartong EG, et al., for the LamLit Study Group. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand. 2010;122(3):246-254. doi:10.1/j.160-047.209.01537.x PubMed
48. Frye MA, Helleman G, McElroy SL, et al. Correlates of treatmentemergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry. 2009;166(2):164-172. doi:10.176/api.ajp.208.0803032 PubMed
49. Rosa AR, Cruz N, Franco C, et al. Why do clinicians maintain antidepressants in some patients with acute mania? Hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study. J Clin Psychiatry. 2010;71(8):1000-1006. doi:10.408/JCP.09m05026gre PubMed
50. Ghaemi SN, Wingo AP, Filkowski MA, et al. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand. 2008;118(5):347-356. doi:10.1/j.160-047.208.01257.x PubMed
51. Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry. 1973;29(3):420-425. PubMed
52. Quitkin FM, Kane J, Rifkin A, et al. Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. A double-blind study. Arch Gen Psychiatry. 1981;38(8):902-907. PubMed (Pubitemid 11040135)
53. Kane JM, Quitkin FM, Rifkin A, et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry. 1982;39(9):1065-1069. PubMed (Pubitemid 12020989)
54. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry. 1984;41(11):1096-1104. PubMed (Pubitemid 14017423)
55. Johnstone EC, Owens DG, Lambert MT, et al. Combination tricyclic antidepressant and lithium maintenance medication in unipolar and bipolar depressed patients. J Affect Disord. 1990;20(4):225-233. doi:10.1016/0165- 0327(90)9054-C PubMed
56. Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol. 2005;20(5):257-264. doi:10.1097/01.yic. 0171519.64080.c9 PubMed (Pubitemid 41192146)
57. Ghaemi SN, El-Mallakh RS, Baldassano CF, et al. Randomized clinical trial of efficacy and safety of long-term antidepressant use in bipolar disorder. Bipolar Disord. 2005;7(suppl 2):59.
58. Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry. 2003;160(7):1252-1262. doi:10.176/api.ajp.160.7.1252 PubMed (Pubitemid 41070941)
59. Tamayo JM, Sutton VK, Mattei MA, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol. 2009;29(4):358-361. doi:10.1097/JCP.0b013e3181ad23f PubMed
60. Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009;12(6):773-782. doi:10.1017/S14614570809735 PubMed
61. Vieta E. Polarity index of mood stabilizers. Poster presented at: IRBD Congress; April 4-6, 2010; Rome, Italy.
62. Popovic D, Reinares M, Amann B, et al. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology (Berl). 2011;213(4):657-667. doi:10.107/s0213-010-2056-8 PubMed
63. Kato T, Kanba S, Terao T, et al. Treatment guidelines of Japanese Society of Mood Disorders, I: bipolar disorders 2011 [in Japanese]. Jap J Clin Psychiatry. 2011;40:507-522.
64. Yoon BH, Bahk WM, Bae SO, et al. Korean medication algorithm for bipolar disorder 2006 (V): maintenance therapy [in Korean]. Korean J Psychopharmacol. 2006;17(6):528-537.
65. Aydemir Ö, Ulusahin A, Akdeniz F, et al. Treatment Guidelines for Bipolar Disorder, Mood Disorders Section, Psychiatric Association of Turkey, Subspecialty Study Sections Publications Series, No: 10. Ankara: Tuna Matbaacilik San. Tic. A.S.; 2010.
66. Strejilevich S, Vázquez GH, Garcia Bonetto G, et al. 2nd Argentine Consensus on the treatment of bipolar disorders. Vertex. 2010;21 (suppl 1):2-55.
67. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication (published correction appears in Arch Gen Psychiatry. 2007;64(9):1039). Arch Gen Psychiatry. 2007;64(5):543-552. doi:10.101/archpsyc. 64.5.543 PubMed (Pubitemid 46718287)
68. Cho MJ, Chang SM, Hahm BJ, et al. Prevalence and correlates of major mental disorders among Korean adults: a 2006 national epidemiologic survey. J Korean Neuropsychiatr Assoc. 2009;48(43):143-152.
69. Kim JH, Cha BS, Ha KS. Trends in pharmacotherapy of the hospitalized patients with bipolar disorder: a twelve-year naturalistic study. (Korean) Korean J Psychopharmacol. 2002;13(1):37-46.
70. Cha B, Kim JH, Ha TH, et al. Polarity of the first episode and time to diagnosis of bipolar I disorder. Psychiatry Investig. 2009;6(2):96-101. doi:10.4306/pi.209.6.2.96 PubMed
71. Jon DI, Bahk WM, Min KJ, et al. Korean medication algorithm for bipolar disorder 2006 (I) [in Korean]. Korean J Psychopharmacol. 2006;17(4):349-361.
72. Jon DI, Bahk WM, Yoon BH, et al. Revised Korean medication algorithm for bipolar disorder [in Korean]. World J Biol Psychiatry. 2009;10(4 pt3): 846-855. doi:10.1080/156297080214865 PubMed
73. Bahk WM, Shin YC, Jon DI, et al. Korean medication algorithm for bipolar disorder (I) [in Korean]. Korean J Psychopharmacol. 2002;13(3):205-221.
74. Vahip S, Aydemir Ö. Mood Disorders Section, Psychiatric Association of Turkey, Subspecialty Study Sections Publications Series, No: 10. In: Aydemir Ö, Ulusahin A, Akdeniz F, eds. Treatment guidelines for Bipolar Disorder. Ankara: Tuna Matbaacilik San. Tic. A.S.; 2010:41-62.
75. Yazici O, Oral ET. Maintenance Treatment. In: Aydemir Ö, Ulusahin A, Akdeniz F, eds. Treatment Guidelines for Bipolar disorder. Mood Disorders Section, Psychiatric Association of Turkey, Subspecialty Study Sections Publications Series, No: 10. Ankara, Turkey: Tuna Matbaacilik San. Tic. A.S.; 2010:63-82.
76. Cipriani A, Pretty H, Hawton K, et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry. 2005;162(10):1805-1819. doi:10.176/api.ajp.162.10.1805 PubMed (Pubitemid 41428610)
77. Vázquez GH, Strejilevich S, García Bonetto G, et al.; Asociación Argentina de Psiquiatría Biológica. [Argentine consensus on the treatment of bipolar disorders]. (Spanish) Vertex. 2005;16(suppl):3-24. PubMed
78. Kupka RW, Luckenbaugh DA, Post RM, et al. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry. 2005;162(7):1273-1280. doi:10.176/api.ajp.162.7. 1273 PubMed (Pubitemid 40905577)
79. Baldessarini RJ, Tondo L, Ghiani C, et al. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010;167(8):934-941. doi:10.176/api.ajp.2010.0906080 PubMed
80. Reed C, Novick D, Gonzalez-Pinto A, et al. Observational study designs for bipolar disorder: what can they tell us about treatment in acute mania? Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(4): 715-721. doi:10.1016/j.pnpbp. 209.03.024 PubMed
81. Vieta E, Berk M, Wang W, et al. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord. 2009;119(1-3):22-27. doi:10.1016/j.jad.209. 02.028 PubMed
82. Nolen WA, Weisler RH, Neijber A, et al. Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. Poster presented at the 17th European Congress of Psychiatry; Jan 24-28, 2009; Lisbon, Portugal.
83. Graham SM, Howgate D, Anderson W, et al. Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf. 2011;10(4):575-602. doi:10.1517/1474038.201.56012 PubMed
84. Monfoulet LE, Rabier B, Dacquin R, et al. Thyroid hormone receptor β mediates thyroid hormone effects on bone remodeling and bone mass. J Bone Miner Res. 2011;26(9):2036-2044. doi:10.102/jbmr.432 PubMed
85. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23-29. PubMed (Pubitemid 28011969)
86. Rakofsky JJ, Dunlop BW. Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review. J Clin Psychiatry. 2011;72(1):81-90. doi:10.408/JCP.09r05815gre PubMed
87. Keck PE Jr, Calabrese JR, McIntyre RS, et al., for the Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68(10):1480-1491. doi:10.408/JCP.v68n103 PubMed (Pubitemid 350073394)
88. Smith LA, Cornelius VR, Azorin JM, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord. 2010;122(1-2):1-9. doi:10.1016/j.jad.209.10.03 PubMed
89. Beynon S, Soares-Weiser K, Woolacott N, et al. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J Psychopharmacol. 2009;23(5):574-591. doi:10.17/0269810809385 PubMed
90. Fehr BS, Ozcan ME, Suppes T. Low doses of clozapine may stabilize treatment-resistant bipolar patients. Eur Arch Psychiatry Clin Neurosci. 2005;255(1):10-14. doi:10.107/s0406-04-0528-8 PubMed
91. Hollon SD, Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. Depress Anxiety. 2010;27(10):891-932. doi:10.102/da.20741 PubMed
92. Colom F, Vieta E, Sánchez-Moreno J, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry. 2009;194(3):260-265. doi:10.192/bjp.bp.107.040485 PubMed
93. Reinares M, Colom F, Sánchez-Moreno J, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord. 2008;10(4):511-519. (Pubitemid 351619167)